The current study is a randomized, open study aimed to compare the effects of conventional glucocorticoid replacement treatment and dual-release hydrocortisone on anthropometric, metabolic, cardiovascular and bone outcomes in treatment-naïve patients with primary adrenal insufficiency and secondary adrenal insufficiency in a 10 year-observation period.
Adrenal insufficiency (AI) can be caused by a disease involving the adrenal gland resulting in inadequate secretion of adrenal cortex hormones, primary adrenal insufficiency (PAI). Secondary adrenal insufficiency (SAI) results from a decreased level of adrenocorticotrophin hormone (ACTH) released from the pituitary gland. The mainstay of treatment of PAI and SAI is glucocorticoid (GC) replacement therapy. Conventional steroid replacement therapy includes cortisone acetate and hydrocortisone administered 2-3 times a day with the highest dose in the morning and the lowest dose in the afternoon. These dosing regimens have been designed to mimic the peak of cortisol secretion in the morning and avoid overdosing during the night hours, even though a higher risk of developing comorbidities has been shown, notably in patients treated with higher evening doses. In patients with AI on conventional steroid replacement therapy, mortality remains higher than in the general population, mainly due to non-physiological daily GC overexposure and to inadequate cortisol exposure during stress-related events and illness. Studies aiming to evaluate the long-term clinical outcomes of patients with AI on conventional steroid replacement therapy clearly showed increased comorbidities, mainly related to the dose used. By contrast, dual-release hydrocortisone (DR-HC) is characterized by once-daily administration with high release of hydrocortisone immediately after intake and a very low release in the evening and nocturnal hours. The switch from conventional GC therapy to DR-HC has been shown to be associated with improvement in BMI, hepatic, bone and glucometabolic parameters and QoL. However, long-term clinical outcomes of patients treated with DR-HC in patients naïve to steroid treatment are not known.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
88
Oral tablets 20-25-30-40 mg/day
Oral tablets 10-15-20-25-37,5-50-62,5 mg/day
Change of body weight
Single outcome measurement of body weight (kg).
Time frame: 0, 5 years, 10 years
Change of anthropometric parameters
waist circumference
Time frame: 0, 5 years and 10 years
Change of metabolic parameters
Composite outcome including evaluation of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides, HbA1c and fasting blood glucose
Time frame: 0, 5 years and 10 years
Change of insulin sensitivity parameters
the Isi-Matsuda index
Time frame: 0, 5 years and 10 years
Change of cardiovascular parameters
Measurement of interventricular septum at diastole (IVSd) and the thickness of the posterior wall (PWT) by high-resolution M-B-mode transthoracic echocardiography
Time frame: 0, 5 years and 10 years
Change of bone metabolic parameters
Composite outcome including calcium, phosphorus, Vitamin D, PTH, creatinine (all measured in mg/dL)
Time frame: 0, 5 years and 10 years
Change of bone density
Bone mineral density quantified by Dual X-Ray Absorptiometry (DEXA)
Time frame: 0, 5 years and 10 years
Change of vascular parameters
Measurement carotid intima media thickness by high-resolution M-B-mode echography
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 0, 5 years and 10 years